FDA Approves Victoza for Children With Type 2

The U.S. Food and Drug Administration (FDA) has approved the injectable medicine Victoza[1] (generic name liraglutide) for children 10 years old and up with type 2 diabetes[2].

Type 2 diabetes is the most prevalent form of the condition, characterized by insufficient insulin release by the pancreas and inefficient use of insulin by the body’s cells. It is becoming increasingly common in children, with new cases in youth expected to quadruple[3] in the next 40 years.


Approved since 2010[4] for adults with type 2, Victoza becomes the only medicine other than insulin and metformin[5] approved for use in children with the condition. A member of the class of medicines known as GLP-1 inhibitors[6], it works by increasing feelings of fullness, slowing stomach emptying, increasing the release of insulin, and decreasing the release of glucagon[7] (a hormone that raises blood glucose).

To get cutting-edge diabetes news, strategies for blood glucose management, nutrition tips, healthy recipes, and more delivered straight to your inbox, sign up for our free newsletter[8]!

“The FDA encourages drugs to be made available to the widest number of patients possible when there is evidence of safety and efficacy,” stated Lisa Yanoff[9], MD, acting director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “Victoza has now been shown to improve blood sugar control in pediatric patients with type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease.”

Want to learn more about type 2 diabetes in children? Read “Recognizing Type 2 Diabetes in Children and Adolescents”[10] and “Children and Type 2 Diabetes: What’s New?”[11]

  1. approved the injectable medicine Victoza: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes
  2. type 2 diabetes: https://www.diabetesselfmanagement.com/diabetes-resources/definitions/type-2-diabetes/
  3. expected to quadruple: https://www.diabetesselfmanagement.com/about-diabetes/diabetes-kids/recognizing-type-2-diabetes-in-children-and-adolescents/
  4. Approved since 2010: https://www.marketwatch.com/story/fda-approves-non-insulin-type-2-diabetes-drug-for-kids-the-first-to-hit-market-in-20-years-2019-06-17
  5. metformin: https://www.diabetesselfmanagement.com/managing-diabetes/treatment-approaches/metformin-2/
  6. GLP-1 inhibitors: https://www.diabetesselfmanagement.com/blog/non-insulin-injectable-diabetes-medications/
  7. glucagon: https://www.diabetesselfmanagement.com/diabetes-resources/definitions/glucagon/
  8. sign up for our free newsletter: https://www.diabetesselfmanagement.com/newsletter/
  9. stated Lisa Yanoff: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes
  10. “Recognizing Type 2 Diabetes in Children and Adolescents”: https://www.diabetesselfmanagement.com/about-diabetes/diabetes-kids/recognizing-type-2-diabetes-in-children-and-adolescents/
  11. “Children and Type 2 Diabetes: What’s New?”: https://www.diabetesselfmanagement.com/about-diabetes/diabetes-kids/children-type-2-diabetes-whats-new/

Source URL: https://www.diabetesselfmanagement.com/blog/fda-approves-victoza-children-type-2/

Diane Fennell: Diane Fennell has been an editor at Diabetes Self-Management magazine since 2003. She is currently the Editorial Director. (Diane Fennell is not a medical professional.)

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.